The Bottom Line Foundayo (orforglipron) is the first oral GLP-1 weight-loss pill that can be taken at any time of day without fasting or food restrictions solving a specific barrier that has limited the real-world usability of oral semaglutide for many patients
The SURPASS-2 trial found that Mounjaro 15 mg produced nearly twice the weight loss of Ozempic 1 mg over 40 weeks in people with type 2 diabetes
Whether you are navigating chronic illness, hormonal transitions, digestive challenges, or simply want to optimize your health, our team is here to support you with integrity, expertise, and a focus on lasting wellbeing
What someone sells you as retatrutide could be underdosed, overdosed, contaminated, or a completely different compound
Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this markets timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval
A new study suggests semaglutide use may help reduce severe knee pain
.png)
